FOSUTI study
About
The FOSUTI study is a world-first study to assess oral Fosfomycin for the treatment of drug-resistant Urinary Tract Infections in children (FosUTI).
The study will involve up to 300 children to compare whether fosfomycin is as good as usual standard treatment to manage urinary tract infections (UTIs).
The FOSUTI study is led by Dr Phoebe Williams, Paediatric Infectious Diseases Clinician at the Sydney Children's Hospital, Randwick, and is a collaborative trial incorporating The Sydney Children's Hospitals Network, Royal Children's Hospital, Perth Children's Hospital and Queensland Children's Hospital. It is sponsored by The University of Sydney and funded by the Medical Research Future Fund (MRFF).
Aim
The FOSUTI study aims to explore the use of an oral antibiotic, fosfomycin, which has been used in adults and young babies safely, to manage drug-resistant UTIs in children.
Learn more
How will we know if fosfomycin works?
Fosfomycin is an antibiotic primarily used to treat lower urinary tract infections.
We will understand if it works in children once we compare the number of children in both groups who return to baseline health at 28 days after enrolment in the study.
We will also compare any side effects and the quality of life between the two groups to work out what the best option for managing drug resistant UTIs may be.
What are the potential benefits of fosfomycin ?
- Shorter hospital stay
- Less invasive procedures
- Decrease risk of promoting antimicrobial resistance (AMR)
Why does it matter?
Antimicrobial resistance (AMR) is spreading globally, and increasingly, these infections are resulting in prolonged hospitalisation to treat infections caused by drug-resistant bacteria or ‘bugs’, as less oral antibiotics are available to manage these resistant infections.
UTIs are one of the most common bacterial infections in children and are becoming more difficult to treat due to antibiotic resistance.
Children have few options for oral treatments of antibiotic resistant UTIs. This means that children often stay in hospital for longer and result in more harm to children (including more attempts at intravenous cannulation).
We are exploring the use of an oral antibiotic, fosfomycin, to help children get out of hospital more quickly and will help provide important information on the best dosing regimens for fosfomycin in children.
Contact
Enquiries
Principal Investigator - Dr Phoebe Williams
Email: SCHN-SCH-ID-Research@health.nsw.gov.au
Phone: 0418 411 602
See more about the team